Table 3.
Clinical and Metadata of Delta and Alpha Vaccinated and Unvaccinated Patients
| Delta | Alpha | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All Positives After Vaccination | True Breakthrough | Unvaccinated | P Value: All Positives After Vaccination to Unvaccinated | P Value: True Breakthrough to Unvaccinated | All Positives After Vaccination | True Breakthrough | Unvaccinated | P Value: All Positives After Vaccination to Unvaccinated | P Value: True Breakthrough to Unvaccinated | P Value/ Alpha to Delta True Breakthrough | |
| Total | 300 | 224 | 485 | 184 | 59 | 1298 | |||||
| Median days after 1st dose (SD) | 195.7 (47.6) | 77.3 (27.9) | <.00001 | ||||||||
| Symptomatic (%) | 252 (84) | 189 (84.4) | 423 (87.2) | .17 | .28 | 148 (80.4) | 36 (61) | 1109 (85.4) | .0424 | <.00001 | .0002 |
| Asymptomatic (%) | 48 (16) | 35 (15.6) | 60 (12.4) | 36 (19.6) | 23 (38.9) | 175 (13.5) | |||||
| Median age | 47 (18.7) | 46 (18.5) | 30 (22.2) | <.00001 | <.00001 | 53 | 51 | 34 | <.00001 | .14 | .130 |
| Females (%) | 193 (64.3) | 149 (66.5) | 257 (53) | .002 | .0008 | 112 (60.9) | 42 (71.2) | 753 (58) | .52 | .06 | .54 |
| Males (%) | 107 (35.6) | 75 (33.5) | 228 (47) | 72 (39.1) | 17 (28.8) | 544 (41.9) | |||||
| Race | |||||||||||
| Asian (%) | 34 (11.3) | 31 (13.9) | 13 (2.7) | 4 (2.2) | 1 (1.7) | 30 (2.3) | |||||
| Black (%) | 83 (27.7) | 53 (23.7) | 211 (43.5) | <.00001 | <.00001 | 73 (39.7) | 13 (22) | 787 (60.6) | <.00001 | <.00001 | .6 |
| White (%) | 161 (53.7) | 124 (55.4) | 172 (35.5) | 86 (46.7) | 38 (64.4) | 330 (25.4) | |||||
| Other/ unknown (%) | 22 (7.3) | 16 (7.1) | 89 (18.4) | 21 (11.4) | 7 (11.9) | 151 (11.6) | |||||
| Disease severity | |||||||||||
| Admitted (%) | 39 (13) | 22 (9.8) | 83 (17.1) | .13 | .012 | 26 (14.1) | 4 (6.8) | 139 (10.7) | .17 | .51 | .6 |
| ICU level care (%) | 13 (4.3) | 9 (4) | 28 (5.8) | .4 | .37 | 8 (4.3) | 2 (3.4) | 46 (3.5) | .53 | 1 | 1 |
| Death (%) | 5 (1.7) | 3 (1.3) | 15 (3.1) | .25 | .2 | 4 (2.2) | 0 | 12 (0.9) | .13 | 1 | 1 |
| Comorbidities | |||||||||||
| Hypertension (%) | 124 (41.3) | 87 (38.9) | 106 (21.9) | .00001 | <.00001 | 91 (49.5) | 26 (44.1) | 369 (28.4) | <.00001 | .0125 | .55 |
| Respiratory failure (%) | 32 (10.7) | 21 (9.4) | 50 (10.3) | .90 | .79 | 24 (13) | 7 (11.9) | 135 (10.4) | .307 | .66 | .6 |
| Pregnancy (%) | 18 (6) | 14 (6.25) | 35 (7.2) | .56 | .75 | 13 (7.1) | 7 (11.9) | 105 (8.1) | .77 | .33 | .16 |
| Lung disease (%) | 50 (16.7) | 33 (14.7) | 74 (15.3) | .60 | .91 | 47 (25.5) | 14 (23.7) | 311 (23.9) | .65 | 1 | .12 |
| Kidney disease (%) | 43 (14.3) | 29 (12.9) | 39 (8) | .006 | .05 | 45 (24.5) | 13 (22) | 159 (12.2) | 0 | .042 | .1 |
| Immunosuppression (%) | 65 (21.7) | 46 (20.5) | 52 (10.7) | .00 | .001 | 53 (28.8) | 15 (25.4) | 198 (15.3) | 0 | .044 | .5 |
| Diabetes (%) | 61 (20.3) | 40 (17.9) | 47 (9.7) | .00 | .003 | 51 (27.7) | 13 (22) | 184 (14.2) | 0 | .127 | .5 |
| Heart failure (%) | 25 (8.3) | 16 (7.1) | 19 (3.9) | .010 | .09 | 29 (15.8) | 10 (16.9) | 91 (7) | .0002 | .0096 | .04 |
| Atrial fibrillation (%) | 25 (8.3) | 14 (6.25) | 18 (3.7) | .009 | .17 | 19 (10.3) | 5 (8.5) | 46 (3.5) | .0002 | .07 | .56 |
| Smoker (%) | 25 (8.3) | 19 (8.5) | 47 (9.7) | .60 | .68 | 25 (13.6) | 5 (8.5) | 187 (14.4) | .8227 | .25 | 1 |
| Cerebrovascular disease (%) | 31 (10.3) | 18 (8) | 22 (4.5) | .002 | .08 | 26 (14.1) | 5 (8.5) | 78 (6) | .0003 | .40 | 1 |
| Cancer (%) | 113 (37.7) | 90 (40.2) | 62 (12.8) | <0.00001 | <.00001 | 87 (47.3) | 31 (52.5) | 231 (17.8) | <.00001 | <.00001 | .1 |
| Coronary artery disease (%) | 50 (16.7) | 34 (15.2) | 43 (8.9) | .0014 | .0140 | 55 (29.9) | 18 (30.5) | 181 (13.9) | <.00001 | .002 | .013 |
| 1 with unknown gender | |||||||||||
All positives after vaccination includes any patient who received vaccination prior to the positive test result. True breakthrough infections were based on the Centers for Disease Control and Prevention (CDC) definition to include positives more than 14 days after the second dose for Pfizer/BioNTech BNT162b2 or Moderna mRNA-1273 or 14 days after the J&J/Janssen shot. Statistics for ages and median days after vaccination were calculated by t test, and all other statistics were calculated by χ2 test.
Abbreviations: ICU, intensive care unit; SD, standard deviation.